Results 211 to 220 of about 349,122 (350)

Prospective evaluation of chemotherapy-induced dyslipidemia in early breast cancer: implications for cardiovascular risk. [PDF]

Front Oncol
Rusinova L, Medvedieva J, Santova Z, Kozarova M.   +3 more
europepmc   +1 more source

Relationships between periodontitis, tooth loss, and metabolic syndrome indicators

Journal of Periodontology, EarlyView.
Abstract Background This study investigates how poor oral health impacts metabolic alterations, specifically evaluating the effects of periodontitis and tooth loss, either individually or in combination, on the number of metabolic syndrome (MetS) indicators.
Verbênia Silva Conceição, Isaac Suzart Gomes‐Filho, Simone Seixas da Cruz, Michelle Santana Xavier Ramos, Ana Claudia Morais Godoy Figueiredo, Soraya Castro Trindade, Daiane Silva Sampaio, Maria Clara Azevedo Moreira, Eneida de Moraes Marcílio Cerqueira, Josicélia Estrela Tuy Batista, Alexandre Marcelo Hintz, Gregory John Seymour, Frank Andrew Scannapieco, Peter Michael Loomer, Johelle de Santana Passos‐Soares   +14 more
wiley   +1 more source

Prevalence of dyslipidemia and associated factors among premenopausal and post-menopausal women: a community-based comparative cross-sectional study in Debre Markos city, Northwest, Ethiopia, 2024. [PDF]

BMC Endocr Disord
Kindie Y, Fetene G, Worede A, Zenaw A, Yechale M.   +4 more
europepmc   +1 more source

Syzygium polyanthum Extract as a therapy for dyslipidemia

, 2021
Satya Agusmansyah
openalex   +1 more source

A retrospective cohort study comparing periodontal regeneration using fibroblast growth factor‐2 versus autologous bone graft

Journal of Periodontology, EarlyView.
Abstract Background Fibroblast growth factor‐2 (FGF‐2) is a novel agent utilized in periodontal regeneration therapy. However, its clinical efficacy compared with autologous bone graft (ABG), a long‐established treatment, remains unclear. This study aimed to compare the clinical outcomes of FGF‐2 and ABG and to assess the impact of patient background ...
Toshiki Matsumoto, Shin Nakamura, Yuki Ito‐Shinoda, Mai Sakamoto, Takayuki Ishii, Yasuki Nonomura, Hidetaka Ideguchi, Keisuke Okubo, Kazu Takeuchi‐Hatanaka, Kazuhiro Omori, Tadashi Yamamoto, Shogo Takashiba   +11 more
wiley   +1 more source

Dyslipidemia

, 2017
Jankowski, Piotr, Kusak, Piotr
  +5 more sources

Serum Apolipoprotein B Levels and Apolipoprotein B/Apolipoprotein A1 Ratio as Predictors of Dyslipidemia Risk in Patients Treated with Second-Generation Antipsychotics: A Retrospective Cohort Study. [PDF]

Neuropsychiatr Dis Treat
Zhang JX, Huang ZQ, Yang JM, Wang WY, Li WN.   +4 more
europepmc   +1 more source

Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype [PDF]

, 2009
Manfredi Rizzo, Kaspar Berneis, Martin Hersberger, Ilenia Pepe, Gaetana Di Fede, Giovam Battista Rini, Giatgen A. Spinas, Enrico Carmina   +7 more
openalex   +1 more source

An Integrative Approach including Panchakarma Therapy, administered in a Spiritual Environment, for the Management of Symptoms Associated with Multiple Complaints Including Polyarthritis, Dyslipidemia, Hypertension and Renal Stone - A Case Study (Case Study 8)

, 2023
Alka Mishra, Saurabh Mishra
openalex   +2 more sources

Ruxolitinib and vedolizumab salvage therapy in the setting of cytomegalovirus colitis for a patient with newly diagnosed very early onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Acute severe ulcerative colitis increases the risk for cytomegalovirus (CMV) infection, particularly with the use of immunocompromising medications. We report a case of a 4‐year‐old with newly diagnosed very early onset inflammatory bowel disease presenting with acute severe colitis refractory to both corticosteroids and infliximab, whose ...
Alison Laxer, Morris Edelman, Julie Gallagher, Benjamin Sahn   +3 more
wiley   +1 more source